This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
Patient-Centric Innovations in MS Care: High-Efficacy DMTs, Cognition, and Special Patient Populations
Balancing Act: Immune Reconstitution vs Immune Suppression
Media formats available:
Details
Presenters
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Mark Freedman, MSc, MD
Professor of Medicine, Neurology
University of Ottawa
Ontario, CanadaDr. Freedman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Sanofi Genzyme Canada
Consulting Fees: Actelion/Janssen (J&J), Alexion/AstraZeneca, Atara Biotherapeutics, Bayer Healthcare, Biogen Idec, Celestra Health, EMD Inc./EMD Serono/Merck Serono, Find Therapeutics, HoffmanLa-Roche, Horizon Therapeutics/Amgen, Neurogenesis, Novartis, Sandoz, Sanofi-Genzyme, Sentrex, Setpoint Medical, Teva Canada Innovation
Ahmed Zayed Obeidat, MD, PhD
Associate Professor, Neurology
Medical College of Wisconsin
Milwaukee, WIDr. Obeidat has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion Pharmaceuticals, Amgen, Banner Life Sciences, BD Biosciences, Biogen, Biologix Solutions, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharmaceuticals, Horizon Therapeutics, Jazz Pharmaceuticals, Novartis, Sandoz, Sanofi-Genzyme, TG Therapeutics, Viela Bio
Reviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate the mechanisms of central nervous system (CNS)-mediated inflammation
- Design new management strategies for multiple sclerosis (MS) that incorporate an advanced understanding of disease pathology and comparative analysis of disease-modifying therapies (DMTs)
- Assess disability progression in MS using patient-reported outcomes (PROs) and cognitive batteries
- Implement routine evaluation of MS fluid and imaging biomarkers for accurate diagnosis, prognosis, and treatment of MS
- Develop tailored management strategies for MS in special populations
- Formulate strategies to optimize and preserve brain health in patients with MS by addressing cognitive dysfunction and overall neurological well-being
Target Audience
This activity has been designed to meet the educational needs of neurologist and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with multiple sclerosis.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/.10 CEUs of pharmacy contact hours.The Universal Activity Number for this program is UAN JA0006235-0000-25-010-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 1/24/26. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.
Commercial Support
This activity is supported by an independent educational grant from Merck Healthcare KGaA.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
